This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

REN-850

Evotec AG

Drug Names(s): REN-850

Description: REN-850 acts by inhibiting leukocyte trafficking and preclinical studies have shown that REN-850 modulates the cell migration driven by multiplechemokine receptors.

Deal Structure: This compound was originally developed by Renovis. In September 2007, Evotec AG and Renovis announced that they have entered into a definitive agreement under which Evotec will acquire Renovis. This acquisition was closed in May 2008.


REN-850 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug